Syntekabio Inc.

We’re thrilled to announce the launch of our groundbreaking Develop Now, Pay Later offer, where we invest in your success! This game-changing opportunity enables pharmaceutical innovators to leverage the power of our AI-driven STB LaunchPad program—without any upfront costs! Here’s what sets it apart: 🔹 Compounds can be validated before you make significant R&D investment 🔹 Highly flexible, physics-based, disease-agnostic AI platform that can identify novel small molecules, antibodies and cancer neoantigens 🔹 Utilizes Flexible Molecular Docking (FMD) to continuously capture protein-ligand interactions/poses. 🔹 Demonstrated outperformance of industry benchmarks 🔹 Coverage of over 70% of human diseases 🔹 Access to over 10 billion compounds as well as 1,400 in vitro/in vivo compatible drug targets 💡 Imagine having the flexibility to initiate high-impact projects without the financial strain. Now you can do just that—innovate boldly with minimized risk. Pay only when you see the agreed validated results. 🔗 Ready to explore this unique opportunity? Learn more about how we can accelerate your R&D strategy: https://lnkd.in/eXC4EuiF #machinelearning #AI #DrugDiscovery #healthcareinnovation #oncology

In today’s fast-paced pharmaceutical landscape, innovation isn’t just an advantage—it’s a necessity. At Syntekabio, we are dedicated to advancing the future of AI driven drug discovery. Our state-of-the-art #AI platform addresses over 70% of human diseases, driving innovation and pushing the boundaries of what's possible.   • Complimentary Feasibility Testing: Evaluate your target compounds with no financial commitment. Our platform provides a risk-free opportunity to assess viability. • Vast Screening Capabilities: Our platform screens over 10 Billion known compounds, using customized precision discovery modeling to target your specific needs. • in vitro/in vivo amenable 1,400 known drug targets: This is a valuable life science community asset as pharmaceutical companies pursue new indications for their drugs by discovering new mode of action and drug repurposing. • Dedicated Supercomputing Power: Each project benefits from a designated supercomputing module, delivering the speed and accuracy needed to stay ahead in drug development.   Syntekabio goes beyond technology; it’s about making innovative possibilities a reality. Our AI powered platforms are designed to reduce the time, cost, and risks involved in drug discovery. We allow you to focus on what really matters: Advancing Human Health.   Ready to redefine your R&D strategy? Let’s collaborate to accelerate the development of innovative, life-saving therapies!   #Biotechnology #Pharma #AI #DrugDiscovery

We offer customizable solutions for preclinical R&D across small molecule and antibody drugs and have developed our own internal pipeline of advanced pre-clinical assets (hits and leads) to key drug targets of interest. Our solutions address critical needs in automation and infrastructure necessary to develop and deploy AI-powered applications, thus allowing our clients to optimize their resources allocation to R&D activities. At BiotechX, we are excited to showcase our both our small molecule discovery platform, and our newly launched in-silico biologics discovery capabilities with 1) Neo-ARS, for cutting-edge neoantigen prediction, and 2) Ab-ARS for the prediction of novel complementarity-determining regions (CDRs) of antibody heavy chains. Syntekabio's mission is to bring novel solutions to patients, faster via our fully automated AI-powered drug discovery and development services.

Following our recent MOU post with BioSeedin, we are excited to share a press release detailing our cooperation plan. We expect this MOU to create great synergy for our business. #MOU #Syntekabio #bioSeedin #AI #DrugDiscovery #Biotech #Pharma #Innovation

Exciting news! Syntekabio has signed a strategic MOU with BioSeedin! Through this MOU, we will effectively leverage BioSeedin's global network for the commercializaion of our active compound assets. #MOU #Syntekabio #BioSeedin #AI #DrugDiscovery #Biotech #Pharma #Innovation

Syntekabio's Advanced #AI Drug Discovery Solutions at BIO International Convention.🔎 💊 We look forward to meetings in our booth 5435! 🙌 Don’t miss the chance to experience cutting-edge#AI drug technology. #AIDrug #InSilico #DrugDiscovery #neoantigen #BIO2024 #BIOInternational #BIOConvention

We're excited to be going to the BIO International Convention 2024 (June 3-6) in San Diego, CA! Visit us at booth 5435 where we'll be showcasing our Advanced #AI Drug Discovery Solutions: DeepMatcher™- This versatile disease-agnostic platform that generates small molecule hits, leads, and drug candidates against multiple targets. Neo-ARS™ & Ab-ARS™ - These in-silico biologics platforms empower researchers with tools for personalized or universal #neoantigen cancer vaccine and novel #antibody drug prediction. Want to learn more about how we can help you bring new, safer, more effective solutions to patients faster? Register to meet with our team through the partnering system or drop by booth 5435 to discover how our innovative AI solutions can address your current pipeline challenges. Schedule a meeting with us through the partnering system: https://lnkd.in/dzYps-9p #drugdiscovery #AI #biotech #BIO2024 #Syntekabio

Syntekabio Inc. is live from the 20th #PEGSummit -- we'll be here all week at Booth #40!

Syntekabio Inc. will be showcasing our AI-based technology for #Neoantigen Prediction and Antibody Drug Discovery at the #PEGSummit in Boston, May 13-17, 2024. Stop by our Booth #40 to learn more. See you there! #PEGSummit #AI #AIDrugDiscovery #AntibodyDrug #GeneTherapy

Discover the Future of AI Drug Discovery with Syntekabio at BIO! 📍 Visit us in Booth #5435 at the San Diego Convention Center, June 3-6, 2024. Explore how Syntekabio de-risks and streamlines drug discovery with our robust #AI-driven platforms. Leveraging our powerful infrastructure, we rapidly discover and deliver both small molecules and biologics, including antibodies and neoantigens. We experimentally validate our work in cooperation with our global CRO network and can deliver a package that’s ready for the clinic. 🧬 Learn more about our innovative solutions: 🔬Syntekabio In Silico Biologics: includes Neo-ARS, our cutting-edge AI platform for personalized or universal #neoantigen prediction, so-called tumor-specific cancer vaccines, as well as Ab-ARS for the prediction of novel complementarity-determining regions (CDRs) of antibody heavy chains. 🚀 STB LaunchPad: proprietary disease-agnostic technology platform that can generate hits, leads, and ultimately drug candidates against multiple targets. 🌟 We look forward to meeting you to tell you more about how our platforms can generate new chemical entities and preclinical assets, simplifying and accelerating the path from discovery to development. 🤝 🗓️ Schedule a meeting via the partnering system at https://lnkd.in/dNYY4ts7 or drop by Booth 5435 to discuss how our innovative solutions can enhance your drug discovery efforts. #BIO2024 #drugdiscovery #BIOInternational #BIOConvention